Listed diagnostics majors delivered robust performance in the June quarter, with most players beating estimates despite the seasonally soft quarter. According to reports from Business Standard, cumulative test volumes grew 11% year-on-year and patient volumes increased 8% year-on-year in Q1 FY27, indicating continued volume-led growth momentum. The sector demonstrated healthy aggregate top-line growth, with operating leverage helping companies expand margins significantly. Operating profit grew 29% year-on-year, while operating profit margin improved 240 basis points to 28.7%, supported by healthy organic growth, resilient B2C demand and improving realisations.
Brokerages maintain positive outlook for the diagnostics sector through FY27, with key players expected to maintain volume growth momentum. As reported by Business Standard, Kotak Research projects healthy sales growth of 18% year-on-year and 11% sequential growth for Dr Lal PathLabs and Metropolis Healthcare, driven by robust volume growth, improved realisations and sustained B2C traction. 360 One Research maintains buy ratings with target prices of ₹1,950 for Dr Lal and ₹700 for Metropolis, while Emkay Research reiterates positive ratings with target prices of ₹2,000 for Dr Lal, ₹675 for Metropolis, and ₹1,500 for Vijaya Diagnostics.
The sector's competitive environment remains stable with flattish pricing trends, helping incumbents gain market share. According to Business Standard, companies have largely maintained pricing year-to-date ending August 26, with no major impact expected from cost inflation due to the West Asia war despite increases in reagent and solvent prices. The September quarter is expected to be seasonally strong, potentially moving past the aggressive pricing-led competitive environment seen in prior years. Focus remains on specialised segments such as genomics, histopathology and high-end radiology, with companies prioritising volume growth, geographic expansion and profitable scale-up.
Key growth drivers include geographic expansion, specialised technology investments, and superior brand equity as customers gravitate towards quality operators. As reported by Business Standard, incumbent diagnostic chains are well-positioned to continue capturing market share through investments in specialised technology, aggressive network expansion and superior brand equity. However, a key risk emerges from hospital chains such as Apollo Hospitals and Max Healthcare venturing into retail diagnostics, which could serve as a headwind for established incumbents with strong healthcare ecosystem presence.
